ZVRA
Zevra Therapeutics Inc.
NASDAQ: ZVRA · HEALTHCARE · BIOTECHNOLOGY
$9.67
-2.32% today
Updated 2026-04-29
Market cap
$585.24M
P/E ratio
7.33
P/S ratio
5.50x
EPS (TTM)
$1.35
Dividend yield
—
52W range
$7 – $13
Volume
1.1M
Zevra Therapeutics Inc. (ZVRA) Financial Forecast & Price Target 2030
Revenue-driven projection model with historical context.
Price target summary
Current price
$9.67
12-Month target
$9.15
2030 Target
—
Intrinsic (DCF)
$22.71
Financial forecast
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | 2027 (E) | 2028 (E) | 2029 (E) | 2030 (E) |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.0B | $0.0B | $0.0B | $0.0B | $0.1B | $0.1B | $0.2B | $0.2B | $0.2B |
| EPS | — | — | — | — | — | — | — | — | — |
CAGR applied: 20.00% (capped 20%) · P/E: 7.33x (capped 25x) · Margin: 78.20%
Methodology
CAGR-based projection model. Research-backed estimates are being generated — check back soon for analyst consensus and management guidance.